The FDA has cleared GSK’s respiratory syncytial virus vaccine for use in adults ages 18 to 49 who are at increased risk for severe disease.
The vaccine, Arexvy, was originally approved in 2023 for use in adults 60 and older. In 2024, the FDA approved expanded use for adults ages 50 to 49 who have a condition that increases their risk of severe RSV complications.
Around 21 million U.S. adults younger than 50 have at least one risk factor for developing severe RSV illness, according to a March 13 news release from GSK. Each year, RSV leads to an estimated 17,000 hospitalizations, 277,000 emergency department visits and nearly 2 million outpatient visits among adults ages 18 to 49 in the U.S.
“This age expansion can help address a significant medical need for adults in the United States at higher risk of severe RSV disease due to certain underlying conditions, and help ease pressure on the healthcare system,” Sanjay Gurunathan, head of vaccines and infectious diseases research and development at GSK, said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
